Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
Expert Opinion on Pharmacotherapy|December 20, 2015
New pharmacotherapy options for multiple myelomaRoberto Mina, Chiara Cerrato, Annalisa Bernardini, et al.
Cancer|December 19, 2018
Minimal residual disease by flow cytometry and allelic-specific oligonucleotide real-time quantitative polymerase chain reaction in patients with myeloma receiving lenalidomide maintenance: A pooled analysisManuela Gambella, Paola Omedé, Stefano Spada, et al.
Oncotarget|October 26, 2016
Minimal residual disease after transplantation or lenalidomide-based consolidation in myeloma patients: a prospective analysisStefania Oliva, Manuela Gambella, Milena Gilestro, et al.
Blood|March 19, 2021
Dose/schedule-adjusted Rd-R vs continuous Rd for elderly, intermediate-fit patients with newly diagnosed multiple myelomaAlessandra Larocca, Francesca Bonello, Gianluca Gaidano, et al.
Blood|January 6, 2016
Triplet vs doublet lenalidomide-containing regimens for the treatment of elderly patients with newly diagnosed multiple myelomaValeria Magarotto, Sara Bringhen, Massimo Offidani, et al.
Haematologica|June 29, 2019
First-line therapy with either bortezomib-melphalan-prednisone or lenalidomide-dexamethasone followed by lenalidomide for transplant-ineligible multiple myeloma patients: a pooled analysis of two randomized trialsAlessandra Larocca, Roberto Mina, Massimo Offidani, et al.
Critical Reviews in Oncology/Hematology|September 11, 2018
Early mortality in myeloma patients treated with first-generation novel agents thalidomide, lenalidomide, bortezomib at diagnosis: A pooled analysisSara Bringhen, Massimo Offidani, Salvatore Palmieri, et al.
Pageof 1